News from the FDA/CDC
FDA/CDC
Austedo approved for treatment of tardive dyskinesia
The drug was also approved in April 2017 to treat chorea associated with Huntington’s disease.
News from the FDA/CDC
Young adults lead the ranks of recently insured
Since 2010, Americans aged 18-29 years have seen a larger drop in their uninsured rate than those younger and older.
FDA/CDC
Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
This is the first FDA approval for a drug to treat levodopa therapy-related dyskinesia in patients with Parkinson’s disease.
News from the FDA/CDC
Safety issues not that unusual in medical offices
Pharmacies may correct or clarify prescriptions, and lab results aren’t ready when needed.
News from the FDA/CDC
Less than half of office visits involve primary care
Patients aged 45 years and over are more likely to see a specialist.
FDA/CDC
Abilify Maintena OK’d by FDA for adults with bipolar I disorder
Approval of the long-acting injectable form of aripiprazole is based on a 52-week withdrawal trial in adults.
FDA/CDC
Pain frequency varies by employment status
Previously employed adults are the most likely to experience daily pain.
News from the FDA/CDC
Substance use treatment cost $34 billion in 2014
Outpatient care represented the largest share, and prescription drugs were a small but quickly growing segment of spending.
News from the FDA/CDC
Outpatient care 35% of mental health costs and growing
Outpatient care represents the largest share of mental health treatment expenditures, and it continues to get larger, while components such as...
News from the FDA/CDC
Opioid prescribing drops nationally, remains high in some counties
The CDC calls for “more consistency among health care providers” when it comes to prescribing opioids.
FDA/CDC
Endo removes Opana ER from market
The move is in compliance with an FDA request citing a spike in abuse of the opioid agonist.